title: Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients.
abstract: Neutralising antibodies develop in 15% of interferon-beta (IFNbeta)-treated patients, causing the reduction of the clinical effects of the treatment. This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. In conclusion, our data suggest the use of GA in NAb-positive patients.
authors.affiliation: Centro di Riferimento Regionale Sclerosi Multipla e Neurobiologia Clinica, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, TO, Italy. sclerosi.multipla@sanluigi.piemonte.it
authors.forename: Marco
authors.initials: M
authors.lastname: Capobianco
authors.forename: Annalisa
authors.initials: A
authors.lastname: Rizzo
authors.forename: Simona
authors.initials: S
authors.lastname: Malucchi
authors.forename: Francesca
authors.initials: F
authors.lastname: Sperli
authors.forename: Alessia
authors.initials: A
authors.lastname: Di Sapio
authors.forename: Alessandra
authors.initials: A
authors.lastname: Oggero
authors.forename: Mauro
authors.initials: M
authors.lastname: Zaffaroni
authors.forename: Angelo
authors.initials: A
authors.lastname: Ghezzi
authors.forename: Antonio
authors.initials: A
authors.lastname: Bertolotto
mesh_terms: D000906:Antibodies / Q000097:blood / Q000187:drug effects* / Q000276:immunology; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D004351:Drug Resistance / Q000187:drug effects / Q000276:immunology; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016899:Interferon-beta / Q000276:immunology* / Q000494:pharmacology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D055502:Secondary Prevention; D016019:Survival Analysis; D013995:Time; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta